• Explore /
  • Poster
  • / Reverce: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan.

Reverce: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan.

Abstract Poster

Authors

Kohei Shitara

Kohei Shitara

National Cancer Center Hospital East, Kashiwa, Japan

Kohei Shitara , Takeharu Yamanaka , Tadamichi Denda , Yasushi Tsuji , Katsunori Shinozaki , Yoshito Komatsu , Yoshimitsu Kobayashi , Junji Furuse , Hiroyuki Okuda , Masako Asayama , Kohei Akiyoshi , Yoshinori Kagawa , Takeshi Kato , Eiji Oki , Takashi Ando , Yasuo Ohashi , Takayuki Yoshino

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

UMIN000011294

Citation

J Clin Oncol 36, 2018 (suppl 4S; abstr 557)

DOI

10.1200/JCO.2018.36.4_suppl.557

Abstract #

557

Poster Bd #

A6

Abstract Disclosures

Similar Posters

First Author: Kohei Shitara

First Author: Yasushi Tsuji

First Author: Nacer Abrouk

First Author: Chiara Cremolini